CORCEPT THERAPEUTICS INC Quarterly Income Tax Expense (Benefit) in USD from Q1 2016 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Corcept Therapeutics Inc quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q1 2016 to Q3 2024.
  • Corcept Therapeutics Inc Income Tax Expense (Benefit) for the quarter ending September 30, 2024 was $5.73M, a 14.4% increase year-over-year.
  • Corcept Therapeutics Inc Income Tax Expense (Benefit) for the twelve months ending September 30, 2024 was $24.5M, a 18.8% increase year-over-year.
  • Corcept Therapeutics Inc annual Income Tax Expense (Benefit) for 2023 was $18.4M, a 24.7% increase from 2022.
  • Corcept Therapeutics Inc annual Income Tax Expense (Benefit) for 2022 was $14.8M, a 18.2% increase from 2021.
  • Corcept Therapeutics Inc annual Income Tax Expense (Benefit) for 2021 was $12.5M, a 51.2% decline from 2020.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $24.5M $5.73M +$723K +14.4% Jul 1, 2024 Sep 30, 2024 10-Q 2024-10-30
Q2 2024 $23.8M $6.11M +$706K +13.1% Apr 1, 2024 Jun 30, 2024 10-Q 2024-07-29
Q1 2024 $23.1M $7.23M +$4.68M +183% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-01
Q4 2023 $18.4M $5.45M -$2.22M -29% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-15
Q3 2023 $20.6M $5.01M +$6.61M Jul 1, 2023 Sep 30, 2023 10-Q 2024-10-30
Q2 2023 $14M $5.4M +$752K +16.2% Apr 1, 2023 Jun 30, 2023 10-Q 2024-07-29
Q1 2023 $13.3M $2.56M -$1.5M -36.9% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-01
Q4 2022 $14.8M $7.68M +$2.99M +63.9% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-15
Q3 2022 $11.8M -$1.6M -$7.44M -127% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-01
Q2 2022 $19.2M $4.65M -$880K -15.9% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-02
Q1 2022 $20.1M $4.05M +$7.6M Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-03
Q4 2021 $12.5M $4.68M -$130K -2.7% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-15
Q3 2021 $12.6M $5.83M +$2.12M +57% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 $10.5M $5.53M -$2.42M -30.4% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 $12.9M -$3.55M -$12.7M -139% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 $25.6M $4.81M -$2.27M -32% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-28
Q3 2020 $27.9M $3.72M -$4.3M -53.6% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-03
Q2 2020 $32.2M $7.95M +$2.32M +41.2% Apr 1, 2020 Jun 30, 2020 10-Q 2021-07-29
Q1 2020 $29.8M $9.12M +$7.34M +412% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 $22.5M $7.08M +$3.15M +80% Oct 1, 2019 Dec 31, 2019 10-K 2022-02-15
Q3 2019 $19.3M $8.01M +$2.03M +34% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-03
Q2 2019 $17.3M $5.63M +$2.63M +87.5% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-04
Q1 2019 $14.7M $1.78M -$2.05M -53.6% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-04
Q4 2018 $16.7M $3.93M +$80.4M Oct 1, 2018 Dec 31, 2018 10-K 2021-02-23
Q3 2018 -$63.6M $5.98M +$6.03M Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-07
Q2 2018 -$69.7M $3M +$2.95M +5900% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-01
Q1 2018 -$72.6M $3.83M +$3.7M +2916% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-09
Q4 2017 -$76.3M -$76.4M -$76.4M Oct 1, 2017 Dec 31, 2017 10-K 2020-02-24
Q3 2017 $129K -$48K -$48K Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-02
Q2 2017 $177K $50K +$50K Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-09
Q1 2017 $127K $127K +$127K Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-09
Q4 2016 $0 $0 Oct 1, 2016 Dec 31, 2016 10-K 2019-02-26
Q3 2016 $0 Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-03
Q2 2016 $0 Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-02
Q1 2016 $0 Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-02
* An asterisk sign (*) next to the value indicates that the value is likely invalid.